Autopsy report · NCT01339910

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

“Accrual terminated as recommended by the data and safety monitoring board.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 6 years 4 months before it stopped.
• 272 participants enrolled.
• Results were posted on the registry 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Medical College of Wisconsin

Sponsor type

University, hospital or other

Conditions

Leukemia, Myelocytic, Acute

Interventions

Fludarabine and Busulfan; Fludarabine and Melphalan; Busulfan and Fludarabine; Busulfan and Cyclophosphamide; Cyclophosphamide and Total Body Irradiation

Participants

272

Sites

32

Countries

United States

Trials that died the same way

• Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors
  “Terminated due to low accrual.” (70% match in meaning)
• Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
  “Terminated prematurely due to low accrual.” (68% match in meaning)
• Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
  “Terminated due to inadequate rate of accrual.” (66% match in meaning)
• eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors
  “Terminated due to slow accrual.” (66% match in meaning)
• Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
  “Terminated due to safety concerns.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.